Serum omentin-1, inflammation and carotid atherosclerosis in patients with non-diabetic chronic kidney disease

Omentin-1 is suggested to affect inversely atherosclerosis (AS). Data about omentin-1 is limited to chronic kidney disease (CKD). Our aim was to examine omentin-1 in non-diabetic CKD patients who are not dialyzed and investigate its relationships with inflammation and carotid AS.We performed a cross-sectional study in 55 non-diabetic CKD patients and 30 healthy controls. Baseline clinical and laboratory data were obtained for all participants. Serum omentin-1 and interleukin-6 (IL-6) levels were measured according to the manufacturer's instructions. Carotic plaque and intima-media thickness (IMT) were assessed by carotid ultrasonography. The homeostasis model assessment of insulin resistance index (HOMA-IR) was used to assess IR.Omentin-1 and IL-6 levels in the patient group were found to be higher than the control group; the differences were statistically significant (p = 0.01 and p = 0.04, respectively). Carotid IMT(mean) was significantly higher in the patient group (p = 0.01). Omentin-1 did not correlate with IL-6 and IMT in the patient group (p = 0.51 and p = 0.76, respectively). In subgroup analysis, omentin-1 levels in patients with carotid plaque were lower than those without carotid plaque (179.5 ± 88.1 ng/ml and 185.9 ± 67.8 ng/ml, respectively). However, the difference was not statistically significant (p = 0.47).We conclude that omentin-1 is higher in not dialyzed non-diabetic CKD and there is no correlation between omentin-1 and IL-6 or carotid IMT(mean).